SCHEMBL9918548

SCHEMBL9918548

C=C1COc2ccc(-n3c(=O)[nH]c4nnc5[nH]ccc5c43)cc2N1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 5/20 0.36
JAK1 P23458 5/20 0.36
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TYK2 P29597 2/20 0.36
MAP3K11 Q16584 1/20 0.34
NR3C2 P08235 6/20 0.32
PKM P14618 1/20 0.32
ADRB2 P07550 1/20 0.31
HTR1A P08908 1/20 0.31
SLC6A4 P31645 1/20 0.31
NR3C1 P04150 1/20 0.31
JAK3 P52333 3/20 0.31
PRKCA P17252 2/20 0.31
PRKCQ Q04759 2/20 0.31
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
RXFP1 Q9HBX9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9921780 0.90 ALDH1A1 (0.47) JAK2JAK1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL9918550 0.81 PRKCA (0.30) MAP3K11PRKCAPRKCQ
SCHEMBL9918554 0.80 PDE3B (0.40) JAK2JAK1MAP3K11HTR1ASLC6A4
SCHEMBL9921771 0.79 KDM4E (0.39) JAK1ALDH1A1SMN1; SMN2MAP3K11JAK3
SCHEMBL9918552 0.73 HTT (0.39) JAK2JAK1ALDH1A1KMT2AJAK3
SCHEMBL9918551 0.71 MAP3K11 (0.35) JAK2JAK1KMT2ATYK2MAP3K11
SCHEMBL9918547 0.69 JAK2 (0.32) JAK2JAK1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL9921664 0.68 MAP3K11 (0.41) JAK2JAK1ALDH1A1KMT2ATYK2
SCHEMBL9918533 0.68 MAP3K11 (0.41) JAK2JAK1ALDH1A1SMN1; SMN2TYK2
SCHEMBL9918555 0.67 SYK (0.36) JAK2JAK1ALDH1A1KMT2ATYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149662-A1 Heterocyclic Compounds as Janus Kinase Inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149662-A1 Heterocyclic Compounds as Janus Kinase Inhibitors JAK2, JAK1, JAK3 JAK2 1/4885JAK1 2/4885ALDH1A1 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.